applications_2

Single-chain variable fragments (scFvs) combine small size with strong binding. Biointron highlights their history, uses in diagnostics and therapy, and production expertise.

From hybridoma to recombinant platforms, Biointron leads innovations in antibody production and engineering, enabling faster, more flexible, and reliable research solutions.

Explore the dual roles of autoantibodies in health and autoimmune diseases, acting as immune defenders and disruptors in lupus, COVID-19, and chronic inflammation.

Combination antibody therapies enhance efficacy by targeting multiple pathways. Biointron showcases synergistic strategies that improve outcomes in cancer and infectious diseases.

Personalized antibody therapies bring precision to treatment. Biointron highlights how monoclonal antibodies and ADCs target cancer, IBD, and other diseases with improved outcomes.

Monoclonal antibodies fight antimicrobial resistance by targeting pathogens and complementing antibiotics. Learn how they expand the arsenal against AMR threats.

Deep learning brings structural modeling of antibodies to new heights. Explore where it succeeds, where it fails, and hybrid strategies that deliver reliable outcomes.

Harnessing big data in antibody engineering means smarter designs. Explore key databases, their contents, and how to use them to benchmark, compare, and innovate.

Structure modeling platforms from AlphaFold to Rosetta guide smarter antibody design. Learn strengths, caveats, and how to pair predictions with experimental validation.

Deep learning models are redefining antibody research. See how architectures and datasets translate into real-world gains in discovery, screening, and optimization.

AI and computational methods accelerate antibody discovery. Discover how algorithms cut wet-lab cycles, predict properties, and expand the reach of modern biotech.

Compare delivery options for antibody‑based therapies—conjugates, nanoparticles, liposomes, and long‑acting platforms—to improve exposure, precision, and patient safety.

Explore next‑generation antibody formats—bispecifics, trispecifics, and modular designs—that unlock new mechanisms, sharpen targeting, and raise the bar for developability.